Our first retrospective analysis on the compassionate use of REGO as a monotherapy or combined with other therapies (ICB or targeted therapies) in advanced melanoma patients showed the most pronounced responses when combining REGO + BRAF/MEKi [21]. Here, BRAF is linked to melanoma.